Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -5.43% is 92% above its 5-year average of -71.36%, near the high end of its 5-year range (-183.79%–-5.43%).
86.12% above its 12-month average of -39.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.90%.
RETURN ON ASSETS (ROA)
-5.43%
RETURN ON ASSETS (ROA) AVG TTM
-39.13%
RETURN ON ASSETS (ROA) AVG 3Y
-79.92%
RETURN ON ASSETS (ROA) AVG 5Y
-71.36%
RETURN ON ASSETS (ROA) AVG 10Y
-79.57%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+86.12%
CURRENT VS 3Y AVG
+93.21%
CURRENT VS 5Y AVG
+92.39%
CURRENT VS 10Y AVG
+93.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+83.17%
vs the sector median at left
vTv Therapeutics Inc.
Market Cap
$78.59M
Return on Assets (ROA)
-5.43%
TTM Avg
-39.13%
3Y Avg
-79.92%
5Y Avg
-71.36%
Market Cap
$78.29M
Return on Assets (ROA)
-38.31%
TTM Avg
-38.33%
3Y Avg
-38.15%
5Y Avg
-51.76%
Market Cap
$79.03M
Return on Assets (ROA)
-41.09%
TTM Avg
-24.80%
3Y Avg
-25.41%
5Y Avg
-25.41%
Market Cap
$78.07M
Return on Assets (ROA)
-136.52%
TTM Avg
-104.53%
3Y Avg
-92.09%
5Y Avg
-76.74%
Market Cap
$79.61M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$77.54M
Return on Assets (ROA)
-902.18%
TTM Avg
-2200.93%
3Y Avg
-2200.93%
5Y Avg
-2200.93%
Market Cap
$80.30M
Return on Assets (ROA)
-70.05%
TTM Avg
-71.47%
3Y Avg
-58.80%
5Y Avg
-51.13%
Market Cap
$76.74M
Return on Assets (ROA)
-30.65%
TTM Avg
-38.63%
3Y Avg
-43.27%
5Y Avg
-38.60%
Market Cap
$81.20M
Return on Assets (ROA)
-110.64%
TTM Avg
-124.68%
3Y Avg
-93.30%
5Y Avg
-78.61%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | $78.59M | -5.43% | -39.13% | -79.92% | -71.36% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -38.31% | -38.33% | -38.15% | -51.76% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | -41.09% | -24.80% | -25.41% | -25.41% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -136.52% | -104.53% | -92.09% | -76.74% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -74.91% | -50.52% | -40.48% | -70.00% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | -902.18% | -2200.93% | -2200.93% | -2200.93% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -70.05% | -71.47% | -58.80% | -51.13% |
| Outset Medical, Inc. (OM)vs › | $76.74M | -30.65% | -38.63% | -43.27% | -38.60% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -110.64% | -124.68% | -93.30% | -78.61% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -26.59% | -23.05% | -19.50% | -17.99% |
ROA
-5.4%
ROE
-6.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.00% |
| 2024-12-31 | -48.25% |
| 2023-12-31 | -183.79% |
| 2022-12-31 | -57.66% |
| 2021-12-31 | -50.98% |
| 2020-12-31 | -57.47% |
| 2019-12-31 | -236.76% |
| 2018-12-31 | -92.43% |
| 2017-12-31 | -57.83% |
| 2016-12-31 | -30.01% |
| 2015-12-31 | -30.04% |
| 2014-12-31 | -278.75% |
| 2013-12-31 | -310.91% |
